CAR NK cells are following closely behind. Cytovia has designed CAR NK cells against three targets: EGFR, GPC3 and CD38. The EGFR candidate is a dual-targeted CAR designed to hit both wild-type ...

Natural killer (NK) cells are the human body’s first line of defense against cancer and infections but tend to get knocked down by treatment with anti-CD38 antibodies. This is because NK cells ...

ONK’s subsequent NK-cell therapy, ONKT102, has a CD38 CAR with optimised affinity and a DR5 TRAIL variant. ONKT102 is designed to treat relapsed or refractory multiple myeloma (MM), a highly ...

Furthermore, SLE NK cells present phenotypic alterations: increased expression of CD38 and altered upregulation of SLAMF7 after activation (3). To date, few studies evaluated the molecular mechanisms ...

NK cells and Dendritic Cells were transiently depleted, while numbers of T cells, B cells and Monocytes in the peripheral blood remained stable. CD38+ memory T cells that were expanded prior to ...

The CD38 receptor occupancy flow cytometry assay was developed to evaluate changes in T cells, B cells, NK cells, monocytes, granulocytes, plasmablasts and plasma cells in whole blood. Additionally, ...

Natural killer (NK) cells act as an important defense against malignancy through their ability to inhibit tumor metastases and destroy solid tumors and hematopoietic tumors. In addition natural killer ...

Gilead Sciences' cell therapy Kite Pharma has bulked up its position in natural killer (NK) cell therapies, pledging up to $2.3 billion for a partnership with Shoreline Bioscience focusing on off ...

Several immune checkpoint genes were significantly upregulated in T/NK cells, including CTLA4, LAG3, PDCD1 and CD38, while myeloid cells highly expressed the immune checkpoints CD40, CD86 and LAG3 ...

[201] Killer cell immunoglobulin-like receptors (KIRs) are receptors expressed on NK cells and a subset of T cells and function as key regulators of NK cell activity. [86] IPH2101 (anti-KIR ...

which engages in developing innovative cell therapy platforms for cancer that can disrupt conventional treatment paradigms and improve patient outcomes. The firm's products include CD38-GEAR-NK ...